SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma slips as its arm recalls Mirtazapine tablets in US

03 Jan 2020 Evaluate

Aurobindo Pharma is currently trading at Rs. 460.70, down by 1.30 points or 0.28% from its previous closing of Rs. 462.00 on the BSE.

The scrip opened at Rs. 461.00 and has touched a high and low of Rs. 462.55 and Rs. 457.65 respectively. So far 12247 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 838.00 on 30-Apr-2019 and a 52 week low of Rs. 389.70 on 14-Nov-2019.

Last one week high and low of the scrip stood at Rs. 469.20 and Rs. 455.50 respectively. The current market cap of the company is Rs. 26953.18 crore.

The promoters holding in the company stood at 51.87%, while Institutions and Non-Institutions held 34.95% and 13.18% respectively.

Aurobindo Pharma’s arm -- Aurobindo Pharma USA Inc is voluntarily recalling Mirtazapine tablets, used for the treatment of major depressive disorder, in the US market. The product is being recalled due to a label error on declared strength.

Mirtazapine tablets are indicated for the treatment of major depressive disorder and are packaged in 500 count bottle.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments. 

Aurobindo Pharma Share Price

1421.65 -14.25 (-0.99%)
24-Apr-2026 11:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1625.25
Dr. Reddys Lab 1315.25
Cipla 1285.00
Zydus Lifesciences 929.80
Lupin 2272.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×